Search Results - "Juan Vidal, O."

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 by Spigel, D.R., Vicente, D., Ciuleanu, T.E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Luft, A., Wolf, J., Antonia, S., Nakagawa, K., Fairchild, J., Baudelet, C., Pandya, D., Doshi, P., Chang, H., Reck, M.

“…Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously…”
Get full text

nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study by Spigel, D.R., Jotte, R.M., Ponce Aix, S., Gressot, L., Morgensztern, D., McCleod, M., Socinski, M.A., Daniel, D., Juan-Vidal, O., Kim, E.S., West, H.J., Chen, T., Bhore, R., Ong, T.J., Gridelli, C., Thomas, M.

Get full text

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study by Passaro, A, Wang, J, Wang, Y, Lee, S-H, Melosky, B, Shih, J-Y, Wang, J, Azuma, K, Juan-Vidal, O, Cobo, M, Felip, E, Girard, N, Cortot, A B, Califano, R, Cappuzzo, F, Owen, S, Popat, S, Tan, J-L, Salinas, J, Tomasini, P, Gentzler, R D, William, Jr, W N, Reckamp, K L, Takahashi, T, Ganguly, S, Kowalski, D M, Bearz, A, MacKean, M, Barala, P, Bourla, A B, Girvin, A, Greger, J, Millington, D, Withelder, M, Xie, J, Sun, T, Shah, S, Diorio, B, Knoblauch, R E, Bauml, J M, Campelo, R G, Cho, B C

“…Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth…”
Get more information

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update by Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

“…To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated…”
Get full text

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping by Zugazagoitia, J., Ramos, I., Trigo, J.M., Palka, M., Gómez-Rueda, A., Jantus-Lewintre, E., Camps, C., Isla, D., Iranzo, P., Ponce-Aix, S., García-Campelo, R., Provencio, M., Franco, F., Bernabé, R., Juan-Vidal, O., Felip, E., de Castro, J., Sanchez-Torres, J.M., Faul, I., Lanman, R.B., Garrido, P., Paz-Ares, L.

“…Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We…”
Get full text

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors by Pros, E., Saigi, M., Alameda, D., Gomez-Mariano, G., Martinez-Delgado, B., Alburquerque-Bejar, J.J., Carretero, J., Tonda, R., Esteve-Codina, A., Catala, I., Palmero, R., Jove, M., Lazaro, C., Patiño-Garcia, A., Gil-Bazo, I., Verdura, S., Teulé, A., Torres-Lanzas, J., Sidransky, D., Reguart, N., Pio, R., Juan-Vidal, O., Nadal, E., Felip, E., Montuenga, L.M., Sanchez-Cespedes, M.

“…The etiology and the molecular basis of lung adenocarcinomas (LuADs) in nonsmokers are currently unknown. Furthermore, the scarcity of available primary…”
Get full text

Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification by Salvador Coloma, C., Lorente, D., Escoin, C., Mendez, J.A., Juan-Vidal, O.

Get full text

Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study by Bondarenko, I., Juan-Vidal, O., Pajkos, G., Kryzhanivska, A., Pápai Székely, Z., Vicente, D., Vynnychenko, I.O., Jones, S., Wang, Y., Jiang, H., Reinmuth, N.

Get full text

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus by Isla, D., de Castro, J., García-Campelo, R., Majem, M., Vicente, D., Juan-Vidal, O.

“…Aim To stablish a consensus on the treatment strategy for advanced non–small-cell lung cancer (aNSCLC) with epidermal growth factor receptor mutation (EGFRm)…”
Get full text

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients by Garde-Noguera, J., Martin-Martorell, P., De Julián, M., Perez-Altozano, J., Salvador-Coloma, C., García-Sanchez, J., Insa-Molla, A., Martín, M., Mielgo-Rubio, X., Marin-Liebana, S., Blasco-Cordellat, A., Blasco-Molla, S., Gironés, R., Marquez-Medina, D., Aparisi, F., Cerda, M. C. Bas, Macia-Escalante, S., Sánchez, A., Juan-Vidal, O.

“…Background Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and…”
Get full text

Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy by Meliàn Sosa, M., Puchades, C., Mendez, J.A., Torres, A., Rodrigo, C., Gimeno, G., Rama, E., Martínez-Castillo, A., Caballero Daroqui, J., Gomez Codina, J., Juan-Vidal, O., Lorente, D.

Get full text

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331 by Reck, M., Vicente, D., Ciuleanu, T., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Wolf, J., Antonia, S.J., Nakagawa, K., Selvaggi, G., Baudelet, C., Chang, H., Spigel, D.R.

Get full text

Development of primary human NSCLC patient derived xenograft and organoids models as a precision approach to tumor treatment by Juan Vidal, O.J., Gandia, C., Pardo-Sánchez, J.M., Benet, M., Aparisi, S., Palanca, S., Ansotegui, E., Jordá, C., Cerón, J.A., Mancheño, N., Sánchez-Céspedes, M., Lahoz, A., Carretero, J., Farràs, R.

Get full text

Current treatment landscape for oligometastatic non-small cell lung cancer by Garde-Noguera, Javier, Martín-Martín, Margarita, Obeso, Andres, López-Mata, Miriam, Crespo, Inigo Royo, Pelari-Mici, Lira, Vidal, Oscar Juan, Mielgo-Rubio, Xabier, Trujillo-Reyes, Juan Carlos, Couñago, Felipe

“…The management of patients with advanced non-small cell lung carcinoma (NSCLC) has undergone major changes in recent years. On the one hand, improved…”
Get full text

Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results by Nakagawa, K., Garon, E.B., Paz-Ares, L., Ponce, S., Corral Jaime, J., Juan Vidal, O., Nadal, E., Kiura, K., He, S., Treat, J., Dalal, R., Lee, P., Reck, M., Novello, S.

Get full text

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p) by Angelats, L., Garcia Campelo, M.R., Bernabe Caro, R., Arriola Aperribay, E., Calvo de Juan, V., Barba Joaquín, A., Vinolas Segarra, N., Gil Moreno, M.D.L.L., Vilà Martinez, L., Juan Vidal, O.J., Vilariño Quintela, N., Cobo, M., Sais, E., Domine Gomez, M., Fernandez Nuñez, N., Coves Sarto, J., Marse Fabregat, R., Esteve Gomez, A.M., Rodríguez-Abreu, D., Carcereny Costa, E.

Get full text

LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients by Garrido Lopez, P., Felip, E., Paz-Ares, L., Majem, M., Moran, T., Gonzalez-Larriba, J.L., Bosch Barrera, J., Trigo Perez, J.M., Garcia Campelo, M.R., Sanchez Torres, J.M., Isla, D., Vinolas Segarra, N., Camps, C., Insa Molla, A., Juan Vidal, O.J., Massutí, B., Paredes Lario, A., Artal-Cortes, A., Lopez-Brea Piqueras, M., Palacios Calvo, J.

Get full text

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] by Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

Get full text

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients by Garde-Noguera, J., Martin-Martorell, P., De Julián, M., Perez-Altozano, J., Salvador-Coloma, C., García-Sanchez, J., Insa-Molla, A., Martín, M., Mielgo-Rubio, X., Marin-Liebana, S., Blasco-Cordellat, A., Blasco-Molla, S., Gironés, R., Marquez-Medina, D., Aparisi, F., Cerda, M. C. Bas, Macia-Escalante, S., Sánchez, A., Juan-Vidal, O.

“…Clinical and Translational Oncology…”
Get full text

1486PRisk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification by Salvador Coloma, C, Lorente, D, Escoin, C, Mendez, J A, Juan-Vidal, O

Get full text